RBC Capital Upgrades Sunesis Pharmaceuticals Inc. (SNSS) to Outperform
Tweet Send to a FriendGet Alerts SNSS Hot Sheet
Price: $5.21 --0%
Rating Summary:
9 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 0 | Down: 2 | New: 2
Rating Summary:
9 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 0 | Down: 2 | New: 2
Trade SNSS Now!
RBC Capital upgraded Sunesis Pharmaceuticals Inc. (NASDAQ: SNSS) from Sector Perform to Outperform, price target raised from $3 to $5.
For an analyst ratings summary and ratings history on Sunesis Pharmaceuticals Inc. click here. For more ratings news on Sunesis Pharmaceuticals Inc. click here.
Shares of Sunesis Pharmaceuticals Inc. closed at $2.74 yesterday, with a 52 week range of $1.01-$3.19.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
For an analyst ratings summary and ratings history on Sunesis Pharmaceuticals Inc. click here. For more ratings news on Sunesis Pharmaceuticals Inc. click here.
Shares of Sunesis Pharmaceuticals Inc. closed at $2.74 yesterday, with a 52 week range of $1.01-$3.19.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: BofA/Merrill Lynch Upgrades Adobe (ADBE) to Buy
- Wells Fargo Upgrades ProLogis (PLD) to Outperform
- Goldman Sachs Upgrades Mizuho Financial Group Inc. (MFG) to Buy
Create E-mail Alert Related Categories
Analyst PT Change, UpgradesRelated Entities
RBC Capital
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
